BiotechTube
LENZ Therapeutics

LENZ Therapeutics

LENZ
United States

LENZ Therapeutics is dedicated to addressing significant unmet needs in ophthalmology, starting with presbyopia, a condition affecting over 1.8 billion people globally. The company's lead product candidates, LNZ100 (aceclidine) and LNZ101 (aceclidine + brimonidine), are designed as once-daily eye drops that temporarily constrict the pupil to create a pinhole effect, thereby improving near vision. With positive Phase 2 data and pivotal Phase 3 trials underway, LENZ aims to bring the first FDA-approved pharmacological treatment for presbyopia to market. The company went public via a merger with Graphite Bio in March 2024 to fund its late-stage development.

lenz-tx.com

LENZ · Stock Price

USD 9.0317.06 (-65.39%)
Market Cap: $285.1M

Historical price data

AI Company Overview

LENZ Therapeutics is dedicated to addressing significant unmet needs in ophthalmology, starting with presbyopia, a condition affecting over 1.8 billion people globally. The company's lead product candidates, LNZ100 (aceclidine) and LNZ101 (aceclidine + brimonidine), are designed as once-daily eye drops that temporarily constrict the pupil to create a pinhole effect, thereby improving near vision. With positive Phase 2 data and pivotal Phase 3 trials underway, LENZ aims to bring the first FDA-approved pharmacological treatment for presbyopia to market. The company went public via a merger with Graphite Bio in March 2024 to fund its late-stage development.

Ophthalmology

Technology Platform

Proprietary ophthalmic formulations based on aceclidine, a muscarinic agonist, designed to modulate pupil size and improve depth of focus for treating presbyopia.

Pipeline

10
10 drugs in pipeline4 in Phase 3
DrugIndicationStageWatch
Aceclidine+Brimonidine combination ophthalmic solution + Ace...PresbyopiaPhase 3
Aceclidine+Brimonidine combination ophthalmic solution + Pla...PresbyopiaPhase 3
Aceclidine+Brimonidine combination ophthalmic solution + Ace...PresbyopiaPhase 3
Aceclidine+Brimonidine combination ophthalmic solution + Ace...PresbyopiaPhase 3
Aceclidine+Brimonidine combination ophthalmic solution + Ace...PresbyopiaPhase 2

Opportunities

LENZ has the opportunity to launch the first aceclidine-based treatment for the massive, underserved presbyopia market.
Positive Phase 3 data could position LNZ101 as a best-in-class product with superior tolerability.
The platform technology also presents opportunities for expansion into other ophthalmic indications requiring pupil modulation or improved depth of focus.

Risk Factors

Key risks include clinical trial failure in ongoing Phase 3 studies, regulatory delays or rejections, intense competition from established and emerging presbyopia drops, and the challenge of commercializing in a crowded market as a new entrant.
Financial runway is sufficient for now but could be pressured by setbacks.

Competitive Landscape

LENZ competes in the emerging pharmacological presbyopia market against AbbVie's Vuity (pilocarpine) and several other late-stage candidates from Orasis, Eyenovia, and Visus Therapeutics. Its primary differentiation is the use of aceclidine, which may offer a better side effect profile regarding distance vision blur and dimness compared to pilocarpine-based competitors.